Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR1 | P30872 | 1/20 | 0.69 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.69 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.69 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.69 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.69 |
| ▸ | GJB2 | P29033 | 1/20 | 0.56 |
| ▸ | PTPN1 | P18031 | 10/20 | 0.53 |
| ▸ | PTPN2 | P17706 | 5/20 | 0.53 |
| ▸ | BCHE | P06276 | 1/20 | 0.53 |
| ▸ | NT5E | P21589 | 1/20 | 0.51 |
| ▸ | CDC25B | P30305 | 6/20 | 0.50 |
| ▸ | PTPN11 | Q06124 | 3/20 | 0.48 |
| ▸ | PTPN6 | P29350 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3147536 | 1.00 | SSTR1 (0.69) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL7155707 | 0.97 | SSTR1 (0.72) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL3065395 | 0.97 | SSTR1 (0.72) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL7541760 | 0.97 | SSTR1 (0.72) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL23343941 | 0.97 | SSTR1 (0.72) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL24122546 | 0.97 | SSTR1 (0.72) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL7148928 | 0.97 | SSTR1 (0.72) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL19400298 | 0.97 | SSTR1 (0.72) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL3065391 | 0.97 | SSTR1 (0.72) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL7545074 | 0.97 | SSTR1 (0.72) | SSTR1SSTR2SSTR4SSTR3SSTR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080027014-A1 | Novel SGLT inhibitors | TANABE SEIYAKU CO., LTD. | 2008-01-31 | — | — | US | disclosed |
| US-5504078-A | α-glucosidase inhibitors | MERRELL DOW PHARMACEUTICALS INC. (US) | 1996-04-02 | — | — | US | disclosed |
| EP-0532668-B1 | NOVEL ALPHA-GLUCOSIDASE INHIBITORS | MERRELL DOW PHARMA (US) | 1995-11-15 | — | — | EP | disclosed |
| EP-0345104-B1 | Novel Alpha-glucosidase inhibitors | MERRELL DOW PHARMA (US) | 1995-11-02 | — | — | EP | disclosed |
| EP-0422975-B1 | Alpha-glucosidase inhibitors | MERRELL DOW PHARMA (US) | 1994-07-27 | — | — | EP | disclosed |
| EP-0532668-A1 | NOVEL -g(a)-GLUCOSIDASE INHIBITORS. | MERRELL DOW PHARMA (US) | 1993-03-24 | — | — | EP | disclosed |
| US-5157116-A | Antidiabetic agents | MERRELL DOW PHARMACEUTICALS INC. (US) | 1992-10-20 | — | — | US | disclosed |
| US-5097023-A | α-glucosidase inhibitors | MERRELL DOW PHARMACEUTICALS INC. (US) | 1992-03-17 | — | — | US | disclosed |
| WO-1991018915-A1 | NOVEL α-GLUCOSIDASE INHIBITORS | MERRELL DOW PHARMACEUTICALS INC. (US) | 1991-12-12 | — | — | WO | disclosed |
| EP-0422975-A1 | Alpha-glucosidase inhibitors | MERRELL DOW PHARMACEUTICALS INC. (US) | 1991-04-17 | — | — | EP | disclosed |
| EP-0422307-A1 | Novel alpha-glucosidase inhibitors | MERRELL DOW PHARMACEUTICALS INC. (US) | 1991-04-17 | — | — | EP | disclosed |
| EP-0389723-A1 | Novel alpha-glucosidase inhibitors | MERRELL DOW PHARMACEUTICALS INC. (US) | 1990-10-03 | — | — | EP | disclosed |
| EP-0390674-A1 | Novel alpha-glucosidase inhibitors | MERRELL DOW PHARMACEUTICALS INC. (US) | 1990-10-03 | — | — | EP | disclosed |
| EP-0345104-A2 | Novel Alpha-glucosidase inhibitors | MERRELL DOW PHARMACEUTICALS INC. (US) | 1989-12-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027014-A1 | Novel SGLT inhibitors | SLC5A1, SLC5A2, SLC10A1 | SSTR1 352/4885SSTR2 328/4885SSTR4 229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.